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Over the past century, the practice of medicine has largely
been reflexive, primarily focusing on treating acute mani-
festations of disease. Advances in the diagnosis and treat-
ment of coronary heart disease have increased the lifespan
and quality of life for many of our patients. However,
despite these laudable achievements, the treatment of cor-
onary atherosclerosis has largely been palliative, treating the
end-stage sequelae. This is illustrated by the fact that the
first manifestation of cardiovascular disease (CVD) in ap-
proximately 50% of patients is still sudden death or acute
myocardial infarction (MI). A dramatic example of this is
the recent sudden death of 33-year-old star baseball pitcher
Darryl Kile of the St. Louis Cardinals. Although he was
asymptomatic until his sudden death, autopsy discovered
80% to 90% stenoses in two of his coronary arteries.
See page 2117
A large body of evidence demonstrates that subclinical
atherosclerosis is present and progresses for many decades
before the onset of clinical manifestations. In a series of
groundbreaking studies, Palinski, Napoli, and colleagues
have provided direct evidence of the fetal origins of athero-
sclerosis by showing that over 50% of the fetuses of mothers
who were hypercholesterolemic during pregnancy had al-
ready developed aortic fatty streaks (1). Strong correlations
were noted between fetal and maternal plasma cholesterol
levels up to the second trimester, which in turn were
proportional to the extent of lesion formation in the fetus.
Of interest, oxidized low density lipoprotein (LDL) was
present even in the earliest lesions, in some cases before the
presence of monocyte/macrophages, supporting a role for
oxidation in the pathogenesis of lesion formation even in
fetal life. They extended these results by showing that aortic
atherosclerosis in children of hypercholesterolemic (during
pregnancy) mothers progressed much more rapidly than did
children of mothers who had been normocholesterolemic,
despite the fact that plasma cholesterol levels of the children
were similar. Further studies in animals have shown that
lesion formation in offspring can be significantly diminished
by treating hypercholesterolemic pregnant mothers with
cholestyramine or antioxidants. These studies demonstrate
that fetal exposure to maternal hypercholesterolemia, rather
than selection of genetic hypercholesterolemia per se, results
in altered gene expression and artery wall metabolism,
which may affect the subsequent response of the artery to
atherogenic stimuli, particularly during childhood and ado-
lescence (1).
Autopsy studies of soldiers dying in combat in Korea and
Vietnam and the PDAY and Bogalusa Heart Studies have
confirmed the presence of aortic and coronary atheroscle-
rotic lesions, even advanced and obstructive lesions, in
young and clinically robust individuals (2–5). Similarly,
Nissen, Tuzcu, and colleagues have demonstrated with
intracoronary ultrasound that 17% of otherwise healthy
heart donors 20 years of age, 37% of those age 20 to 29,
60% of those 30 to 39, 71% of those 40 to 49, and 85% of
those 50 years old had evidence of coronary atherosclero-
sis, even without “overt” hypercholesterolemia (6). In con-
trast, only 8% of these individuals had angiographic evi-
dence of disease, and none had obstructive disease.
Familial hypercholesterolemia (FH) is an autosomal
dominant disorder resulting from the absence of functional
LDL receptors (7). The homozygous form of this disorder
(HFH) is rare (1:1,000,000) but is the best proof of the
primacy of LDL in contributing to the pathogenesis of
atherosclerosis. Patients with HFH, maintaining plasma
LDL cholesterol levels of 500 to 1,000 mg/dl, have been
documented to have MIs as early as 18 months of age and
usually succumb to various manifestations of ischemic car-
diovascular disease by the third decade of life. Heterozygous
FH (1:500) results in LDL cholesterol levels of 200 to 350
mg/dl and greatly accelerated atherosclerosis, with 30% of
affected males having a major cardiovascular event by age
30. By age 60, 60% of FH males will be affected compared
with only 10% of non-affected male siblings. Even 30% of
FH females will have coronary artery disease by age 60 (7).
One of the earliest manifestations of subclinical athero-
sclerosis is endothelial dysfunction, which is a strong marker
for underlying vascular disease and, in adults, predicts risk of
subsequent cardiovascular events (8,9). The common un-
derlying distal defect in most cases of endothelial dysfunc-
tion is the inability to preserve nitric oxide responsiveness,
either through decreased production or increased destruc-
tion such as through increased oxidative stress (10). There is
evidence that both acute and long-term reductions in LDL
cholesterol, both with diet or pharmacologic therapy, im-
prove endothelial function. For example, Tamai et al. (11)
showed in patients with FH that significant increases in
brachial artery acetylcholine-induced flow mediated dilation
(FMD) were noted within 4 h following a single session of
LDL apheresis, which reduced LDL cholesterol from 142
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to 33 mg/dl. Interestingly, plasma levels of oxidized LDL
and the production in nitrate/nitrite most strongly corre-
lated with the degree of FMD (11). Similarly, the extent of
susceptibility of plasma LDL to oxidation and the presence
of elevated plasma OxLDL levels, measured by antibody
E06, has been strongly correlated with endothelial dysfunc-
tion (12,13). Other studies have shown that statins, fibrates,
cholestyramine, probucol, intraarterial infusion of antioxi-
dants, and dietary therapy also improve endothelial func-
tion. Interestingly, statins may have additional cholesterol-
independent “pleiotropic” effects in preserving endothelial
function by acutely enhancing eNOS activity (14).
In this issue of the Journal, de Jongh and colleagues (15)
have performed a seminal study showing normalization of
endothelial function with simvastatin in children with
heterozygous FH (age  14 years, LDL  205 mg/dl).
They randomized 50 children with FH in a double-blinded
manner to an escalating dose of simvastatin (maximum dose
40 mg/day) versus matching placebo. After 28 weeks of
treatment, coincident with a 40% reduction in LDL cho-
lesterol (to 123 mg/dl), there was normalization of FMD to
levels observed in non-FH controls. Because of ethical
concerns, nitroglycerin was not administered to rule out
endothelium-independent vasodilation, although this is un-
likely to have contributed. In this short treatment period, no
adverse clinical events, hepatic toxicity, or rhabdomyolysis
were noted. Although endothelial dysfunction has been
previously noted in children, this is the first study to show
that endothelial function can be normalized with statin
therapy in children. Although data are not currently avail-
able, it seems reasonable to infer that endothelial dysfunc-
tion will be a prognosticator of CVD in children as in
adults, although the expression of cardiovascular events will
be delayed.
Can the findings from de Jongh et al. (15) be applied to
children and young adults with moderate elevations of LDL
cholesterol? A strong case can be made that any total plasma
cholesterol level above 150 mg/dl is elevated and places one
at risk, depending on the presence of other risk factors. For
example: 1) LDL levels in most animals and even in human
umbilical cord blood are 40 mg/dl; 2) individuals with
hypobetalipoproteinemia with plasma LDL levels 5 to 10
mg/dl seem never to develop atherosclerosis and are long-
lived; 3) atherosclerosis cannot be induced in animals,
without exception, unless their LDL cholesterol levels are
significantly increased; 4) data from epidemiologic studies in
multiple countries have shown that, in general, the increase
in risk for MI starts above a total cholesterol of 150 mg/dl;
5) lowering LDL is proportional to lowering cardiovascular
risk (16); and 6) lowering LDL cholesterol in adults
decreases risk at all levels of LDL studied (17).
In light of the arguments given above, it seems likely that
all would agree that identification and treatment of FH
children and those with moderately elevated LDL choles-
terol levels should begin at an “early age.” The key question
is: “How early should this occur?” Should this be in the
teenage years? Should it be in children before puberty?
Unless we intend to initiate therapy, be it lifestyle modifi-
cations or drug therapy, it makes little sense to identify
patients at such a young age. Such a position requires the
demonstration that the use of hypolipidemic drugs at such a
young age, particularly the statins, fulfills two criteria: first,
that the use of statins and other hypolipidemic agents are
safe in both the short and long term, and second, that
treatment at such a young age has some demonstrable
benefits, both short- and long-term. There is little data to
support the first criterion, but the first evidence to support
the latter is now available with the study of de Jongh et al.
(15). Although there are several studies showing short-term
(48 weeks) safety and efficacy of statins in children (18),
long-term data are unavailable (19); nor is there information
on the long-term safety of the use of bile acid binding resins,
fibrates, niacin, or ezetimibe in such groups. Thus, demon-
stration projects to determine the safety of hypolipidemic
drugs in this patient population, and in particular the use of
statins, are urgently needed before the wide-scale adoption
of this aggressive approach can be advocated.
Cholesterol lowering probably provides protection by
multiple mechanisms, some working very quickly, as noted
in the Myocardial Ischemia Reduction with Aggressive
Cholesterol Lowering (MIRACL) trial (20), and others by
decreasing the progression of atherosclerosis itself and even
inducing long-term regression (21,22). Thus, initiating
diagnosis and treatment early in life in the highest risk
individuals, such as children and young adults with type 1
diabetes, seems the most rational approach. In addition,
children and young adults with multiple risk factors, meta-
bolic syndrome, strong family history such as a first-degree
relative dying in their 40s or 50s, and those on the extremes
of high LDL (160 mg/dl), low HDL (35 mg/dl), or
elevated Lp(a) (50 mg/dl), would be reasonable candidates
for early and aggressive therapy. Although the approximate
30% relative risk reduction in the statin cholesterol-lowering
trials may seem large, the actual incidence of major cardio-
vascular events after statin therapy remains very high, at
least during the 5-year duration of these trials (16,17).
However, there was continued separation of survival curves
at the end of the study period, and it is quite likely that
further significant benefit would have accrued with longer
treatment, or more importantly, with earlier initiation of
treatment.
Assuming that effective treatments are available for chil-
dren and adolescents, how will subclinical atherosclerosis be
diagnosed? It is unlikely the simply measuring plasma
cholesterol levels, except in children with FH, will provide
enough prognostic power. Additional surrogate markers of
atherosclerosis, such as C-reactive protein, markers of oxi-
dized LDL (23), or inflammatory markers, may provide
additional predictive power. In addition, direct non-invasive
imaging of the vessel wall will likely play an important role
in deciding who should be targeted for more aggressive
treatment. Future imaging techniques, however, will need to
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provide prognostic information above and beyond any easily
measured plasma marker of risk.
Potential difficulties in targeting young, asymptomatic,
overtly healthy but at-risk individuals may include poor
compliance, uncertainty of long-term safety and efficacy, the
predictive ability of diagnostic modalities, cost effectiveness
in an era of cost containment, insurability, the potential
adverse effects of statins in pregnancy, and many others.
Armed with knowledge that atherosclerosis starts in
childhood and is directly responsible for the death of nearly
50% of Americans, a change in the paradigm to initiate early
diagnosis, treatment, and prevention should be instituted.
As we move into the 21st century, the challenge before the
cardiovascular community as a whole will be to continue to
improve treatments for CVD but, even more importantly, to
develop cost-effective means to diagnose, prevent, and treat
subclinical disease before death and disability ensue.
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